Robert L Cleek from Arvada, CO, age 61

Us Patents

Immobilized Biologically Active Entities Having A High Degree Of Biological Activity
view source
US Patent:

8021677, Sep 20, 2011
Filed:

Nov 9, 2007
Appl. No.:

11/938162
Inventors:

Robert L. Cleek - Flagstaff AZ, US
Michael D. Daly - Flagstaff AZ, US
Krzysztof R. Pietrzak - Flagstaff AZ, US
Assignee:

Gore Enterprise Holdings, Inc. - Newark DE
International Classification:

A61F 2/00
US Classification:

424423
Abstract:

The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.

Thermoplastic Fluoropolymer-Coated Medical Devices
view source
US Patent:

8048440, Nov 1, 2011
Filed:

Mar 16, 2006
Appl. No.:

11/378401
Inventors:

James W. Chang - Flagstaff AZ, US
Robert L. Cleek - Flagstaff AZ, US
Edward H. Cully - Flagstaff AZ, US
Michael J. Vonesh - Flagstaff AZ, US
Assignee:

Gore Enterprise Holdings, Inc. - Newark DE
International Classification:

A61F 2/82
US Classification:

424423
Abstract:

A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used.

Immobilized Biologically Active Entities Having A High Degree Of Biological Activity
view source
US Patent:

8409604, Apr 2, 2013
Filed:

Aug 11, 2011
Appl. No.:

13/208220
Inventors:

Robert L. Cleek - Flagstaff AZ, US
Michael D. Daly - Flagstaff AZ, US
Krzysztof R. Pietrzak - Flagstaff AZ, US
Assignee:

W. L. Gore & Associates, Inc. - Newark DE
International Classification:

A61F 2/00
US Classification:

424423
Abstract:

The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.

Immobilized Biologically Active Entities Having A High Degree Of Biological Activity Following Sterilization
view source
US Patent:

8496953, Jul 30, 2013
Filed:

May 12, 2006
Appl. No.:

11/433105
Inventors:

Robert L. Cleek - Flagstaff AZ, US
Michael D. Daly - Flagstaff AZ, US
Krzysztof R. Pietrzak - Flagstaff AZ, US
Assignee:

W. L. Gore & Associates, Inc. - Newark DE
International Classification:

A61F 2/00
US Classification:

424423
Abstract:

The present invention is directed to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.

Heparin Entities And Methods Of Use
view source
US Patent:

8591932, Nov 26, 2013
Filed:

Sep 17, 2009
Appl. No.:

12/561927
Inventors:

Robert L. Cleek - Flagstaff AZ, US
Paul D Drumheller - Flagstaff AZ, US
Mei Li - Flagstaff AZ, US
Nora Mardirosian - Bellemont AZ, US
Assignee:

W. L. Gore & Associates, Inc. - Newark DE
International Classification:

A61F 2/02
US Classification:

424423
Abstract:

The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.

Thermoplastic Fluoropolymer-Coated Medical Devices
view source
US Patent:

8609125, Dec 17, 2013
Filed:

Oct 27, 2011
Appl. No.:

13/282892
Inventors:

James W. Chang - Flagstaff AZ, US
Robert L. Cleek - Flagstaff AZ, US
Edward H. Cully - Flagstaff AZ, US
Michael J. Vonesh - Flagstaff AZ, US
Assignee:

W. L. Gore & Associates, Inc. - Newark DE
International Classification:

A61F 2/02
US Classification:

424423
Abstract:

A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used.

Thermoplastic Fluoropolymer-Coated Medical Devices
view source
US Patent:

20040024448, Feb 5, 2004
Filed:

Aug 5, 2002
Appl. No.:

10/213126
Inventors:

James Chang - Flagstaff AZ, US
Robert Cleek - Flagstaff AZ, US
Edward Cully - Flagstaff AZ, US
Michael Vonesh - Flagstaff AZ, US
International Classification:

A61F002/06
US Classification:

623/001420, 623/001460
Abstract:

A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used. The desirable mechanical characteristics are surprising given the absence of cross-linking monomers and curing agents that would otherwise render such materials inadequately biocompatible. The perfluoroalkylvinylether may be perfluoromethylvinylether, perfluoroethylvinylether or perfluoropropylvinylether.

Therapeutic Microparticles
view source
US Patent:

20050175709, Aug 11, 2005
Filed:

Dec 9, 2004
Appl. No.:

11/008820
Inventors:

Ace Baty - Flagstaff AZ, US
Robert Cleek - Flagstaff AZ, US
Daniel Davidson - Flagstaff AZ, US
Melissa Matzen - Flagstaff AZ, US
Michael Vonesh - Flagstaff AZ, US
Joshua Williams - Tucson AZ, US
International Classification:

A61K009/14
US Classification:

424489000
Abstract:

Biodegradable, compression resistant microparticles adapted for injection through a catheter system, such as is useful for selective embolization procedures. The microparticles can optimally be neutrally buoyant relative to a target bodily fluid. Various active agents may be included in the microparticles, such an anesthetic which can reduce pain during an embolization procedure. The invention further comprises methods and equipment for testing and delivering compression resistant microparticles.